Trading update

Tristel PLC
25 July 2023


("Tristel" or the "Company")


Trading update


Tristel plc (AIM: TSTL), the manufacturer of infection prevention products, provides a trading update for the year ended 30 June 2023, ahead of its Open Day for shareholders being held today.


Demand for Tristel's infection prevention products for medical device decontamination and for the sporicidal disinfection of surfaces continues to be very robust across all key geographical markets.


As a result, revenues for the year were up 16% to £36.0m (FY 2022: £31.1m), ahead of consensus forecasts and above the Company's long-term target for revenue growth. Adjusted profit before tax (adjusted for share-based payments) will be slightly ahead of consensus forecasts of £6m. Tristel continues to be debt free and cash generative. Cash balances on 30 June 2023 were £9.5m (30 June 2022: £8.9m).


During the year a total of 17m disinfection events took place using Tristel's chemistry, up 8.2% on the previous year (FY 2022: 15.7m disinfection events). This is also 42% higher than in the year before COVID temporarily disrupted Tristel's normal operational performance (FY 2019: 12m disinfection events).


Paul Swinney, CEO of Tristel plc, comments: "I am delighted to confirm to shareholders that the business continues to deliver a strong trading performance and growth ahead of both analyst expectations and our own growth targets.


"In early June we achieved a major milestone by obtaining approval from the US Food and Drug Administration for our Tristel ULT disinfectant for ultrasound instruments. We are now manufacturing and marketing our products in the USA and Canada and starting to expand in Latin America. We look forward to updating shareholders on our commercial progress in these markets as we continue through the financial year.


"Looking forward to the years ahead, I am confident that Tristel will truly become a leading global player in the infection prevention industry. We now have access to the world's largest ultrasound market for our high-level medical device decontamination products and we have an exciting pipeline of new product innovations supported by a strong balance sheet. We are very excited about the prospects for further growth and the outlook is positive."


A recording of the presentation that will be delivered to shareholders today will be made available on the Company's website, shortly after the event here:


The information communicated in this announcement is inside information

for the purposes of Article 7 of Regulation 596/2014.


For further information please contact:     


Tristel plc

Tel: 01638 721 500

Paul Swinney, Chief Executive Officer

Liz Dixon, Chief Financial Officer

Walbrook PR Ltd

Tel: 020 7933 8780 or

Paul McManus

Mob: 07980 541 893

Lianne Applegarth

Mob: 07584 391 303


Tel: 020 7220 0500

Geoff Nash/ Charlie Beeson (Corporate Finance)

Alice Lane (ECM)


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.


Tristel (TSTL)
UK 100

Latest directors dealings